Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508607 | 0.91 | ALDH1A1 (0.31) | GAA | |
| SCHEMBL508340 | 0.75 | CES2 (0.30) | CES2CES1 | |
| SCHEMBL7136499 | 0.71 | CES2 (0.42) | CES2CES1RECQLGAAHPGD | |
| SCHEMBL3826078 | 0.71 | SMN1; SMN2 (0.39) | CES2CES1SMN1; SMN2 | |
| SCHEMBL2600355 | 0.70 | — | — | |
| SCHEMBL957954 | 0.69 | ALDH1A1 (0.46) | HPGDSMN1; SMN2 | |
| SCHEMBL28124610 | 0.69 | LMNA (0.38) | — | |
| SCHEMBL18800990 | 0.68 | HSD17B10 (0.33) | — | |
| SCHEMBL12693238 | 0.68 | CHRNB2 (0.31) | — | |
| SCHEMBL14045052 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008047224-A1 | PYRAZOLYL-4-OXY-BENZONITRILE DERIVATIVES USEFUL IN TREATING ENDOMETRIOSIS | PFIZER LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047224-A1 | PYRAZOLYL-4-OXY-BENZONITRILE DERIVATIVES USEFUL IN TREATING ENDOMETRIOSIS | PFIZER LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096950-A1 | Compounds Useful In Therapy | CYP19A1, LPXN, HSD17B11 | CES2 1183/4885CES1 623/4885RECQL 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.